These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6542790)

  • 1. Toxicological studies with a novel synthetic anthracycline, the bis-hydrazone bridged analog of 4-demethoxydaunorubicin (SC-33428).
    Zbinden G; Beilstein AK; Bachmann E
    Arzneimittelforschung; 1984; 34(10):1298-301. PubMed ID: 6542790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.
    Formelli F; Casazza AM; Di Marco A; Mariani A; Pollini C
    Cancer Chemother Pharmacol; 1979; 3(4):261-9. PubMed ID: 294954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines.
    Cini-Neri G; Neri B
    Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential.
    Della Torre P; Podestà A; Imondi AR; Moneta D; Sammartini U; Arrigoni C; Terron A; Brughera M
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):355-60. PubMed ID: 11345653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic precursor cells in mice treated with 4-demethoxydaunorubicin and doxorubicin.
    Massa G; Bogliolo G; D'Amore F; Muzzulini C; Ghio R; Pannacciulli I
    J Natl Cancer Inst; 1982 Jun; 68(6):971-6. PubMed ID: 6953276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.
    Broggini M; Italia C; Colombo T; Marmonti L; Donelli MG
    Cancer Treat Rep; 1984 May; 68(5):739-47. PubMed ID: 6586294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
    Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
    Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of doxorubicin (Adriamycin) and 4-demethoxydaunorubicin (Idarubicin) in the conscious rat.
    Christoffersen PS; Rasmussen KK; Hermansen K
    Pharmacol Toxicol; 1988 Jan; 62(1):54-6. PubMed ID: 3162769
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro formation of a toxic aglycone metabolite of 4-demethoxydaunorubicin in conditions that parallel the stomach.
    Cummings J; Milroy R
    Anticancer Res; 1986; 6(5):1177-9. PubMed ID: 3467647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP technical report on toxicity studies of urethane in drinking water and urethane in 5% ethanol administered to F344/N rats and B6C3F1 mice.
    Chan PC
    Toxic Rep Ser; 1996 Mar; (52):1-91, A1-9, B1-9 passim. PubMed ID: 11803705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats.
    Zbinden G; Brändle E
    Cancer Chemother Rep; 1975; 59(4):707-15. PubMed ID: 1175165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma.
    Stanton G; Casper ES; Friedman B
    Cancer Treat Rep; 1985; 69(7-8):915-6. PubMed ID: 3860298
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cardiotoxic and myelosuppressive activity of various antitumor antibiotics of the anthracycline type in the rat].
    Hoffmann H; Härtl A; Amlacher R; Güttner J; Fritsch RS
    Arch Geschwulstforsch; 1983; 53(5):429-39. PubMed ID: 6651471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total chemical synthesis and antitumor evaluation of 4-demethoxy-10,10-dimethyldaunomycin.
    Alexander J; Khanna I; Lednicer D; Mitscher LA; Veysoglu T; Wielogorski Z; Wolgemuth RL
    J Med Chem; 1984 Oct; 27(10):1343-7. PubMed ID: 6481770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of 4-demethoxydaunorubicin.
    Bonfante V; Ferrari L; Villani F; Bonadonna G
    Invest New Drugs; 1983; 1(2):161-8. PubMed ID: 6590530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental systemic toxicology of 4'-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent.
    Bertazzoli C; Rovero C; Ballerini L; Lux B; Balconi F; Antongiovanni V; Magrini U
    Toxicol Appl Pharmacol; 1985 Jul; 79(3):412-22. PubMed ID: 3862266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat.
    Jensen RA; Acton EM; Peters JH
    Cancer Res; 1984 Sep; 44(9):4030-9. PubMed ID: 6744318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.